CARsgen Therapeutics Unveils Promising Results for CT1182, Their Novel CAR-T Product Candidate

CARsgen Therapeutics Unveils CT1182 Clinical Results



CARsgen Therapeutics Holdings Limited recently presented early clinical findings for their innovative CAR-T cell therapy, CT1182 (KJ-C2529), developed to target CD19 and CD20 for patients suffering from relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data emerging from this trial offer not only insights into safety but also show promising signs of efficacy, potentially reshaping treatment approaches for patients facing aggressive forms of lymphoma.

Clinical Trial Overview


The clinical trial, which seeks to explore the efficacy and safety of CT1182, has been ongoing with a focus on aggressive lymphoma types. As of October 31, 2026, the trial explored doses ranging from 1.2 × 10⁸ TU to 7.2 × 10⁸ TU. The study enrolled six patients; five presented with diffuse large B-cell lymphoma (DLBCL), while one had blastoid mantle cell lymphoma (MCL). Notably, all participants had Ann Arbor Stage IV disease, indicating advanced stages of cancer and a median of three prior treatment lines, coupled with a significant total tumor burden averaging 1,927.5 mm².

The follow-up period for the patients has averaged approximately 3.2 months. Among those evaluated for efficacy, three patients achieved a complete response (CR), and two achieved a partial response (PR). The responses observed were particularly notable given the prior treatments these patients had undergone, emphasizing the potential for CT1182 to elicit robust responses even in tough cases.

Safety Profile and Observations


The safety aspect remains a cornerstone of any therapy, especially in oncology. The data revealed that among the six patients evaluated for dose-limiting toxicity (DLT), no serious treatment-related adverse events occurred, nor were there any reported cases of dose-limiting toxicities or infusion-related reactions. Only one instance of Grade 3 leukopenia was noted, which could not be entirely attributed to the treatment, indicating a favorable safety profile.

Interestingly, the responses have shown durability, with one CR lasting nearly five months. It's crucial to highlight that treatment also successfully achieved complete B-cell aplasia in all responding patients, suggesting CT1182’s capabilities could extend beyond oncology into autoimmune disorders based on this immunological impact.

Future Directions


The promising results from this trial set the groundwork for CARsgen Therapeutics to further expand their research efforts. Plans are in place to explore a broader dose range to identify the recommended Phase 2 dose (RP2D) and to optimize the dose-response relationship effectively. The company is also eyeing a registrational clinical trial submission in the first half of 2027 to bring their groundbreaking therapy closer to market, providing hope to patients experiencing the challenges of aggressive B-cell malignancies.

The CARvivo™ Platform


Central to the development of CT1182 is CARsgen's proprietary CARvivo™ platform, which features innovative viral envelopes and T-cell-specific promoters. This technology offers enhanced transduction efficiency and specificity for T-cells, significantly reducing the risks of off-target effects and providing a controlled environment for CAR-T cell generation.

About CARsgen Therapeutics


Founded to address unmet needs in medical treatments, CARsgen not only focuses on hematologic malignancies but also sets its sights on solid tumors and autoimmune diseases. With capabilities spanning from target discovery to commercial-scale production, CARsgen is poised to emerge as a leader in the biopharmaceutical arena, dedicated to providing innovative and effective therapy solutions for patients worldwide.

CARsgen Therapeutics continues to pave its path in the evolving landscape of cancer therapies, and with CT1182 showing promise, the future looks bright for innovative cancer care methodologies.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.